secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001683168-24-007858
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors
--------------------------------------------------------------------------------

- First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.
- Trial is safety, feasibility, dose-finding for Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
- Two-month run-in on anti-PD-1 therapy; if no tumor improvement, patient treated with Hemopurifier.
- Trial targets 9-18 patients; primary endpoint is adverse events and safety lab changes.
- Exploratory endpoints measure extracellular vesicle reduction and T cell activity improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824007858/0001683168-24-007858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824007858/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer